过继性免疫疗法在黑色素瘤中的研究进展  

Advance in adoptive immunotherapy on melanoma

作　　者：高子煦 卫传元 周宇红 顾建英 Gao Zixu;Wei Chuanyuan;Zhou Yuhong;Gu Jianying(Department of Plastic Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Medical Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院整形外科,上海200032 [2]复旦大学附属中山医院肿瘤内科,上海200032

出　　处：《中华整形外科杂志》2023年第1期95-100,共6页Chinese Journal of Plastic Surgery

基　　金：国家自然科学基金面上项目(81972559);上海申康医院发展中心临床三年行动计划(SHDC2020CR2067B)。

摘　　要：黑色素瘤是恶性程度最高的皮肤肿瘤,具有早期易发生转移、患者预后差等特点。近年来,过继性免疫疗法作为一种新兴免疫疗法,在实体瘤治疗中取得重大突破,以肿瘤浸润淋巴细胞为代表的过继性免疫疗法在黑色素瘤中疗效显著,与免疫或靶向联合治疗是未来发展方向,而针对过继性免疫疗法的大规模临床研究尚待开展。该文就过继性免疫疗法在黑色素瘤中的研究进展作一综述。Melanoma is the most malignant skin tumor,which is characterized by early metastasis and poor prognosis.In recent years,adoptive immunotherapy,as a new immunotherapy,has made great breakthrough in treatment of solid tumors.Represented by tumor-infiltrating lymphocyte,adoptive immunotherapy exhibits remarkable effects in melanoma.Its combination with immunotherapy or targeted therapy will be a certain trend for future development,while the large-scale clinical study on adoptive immunotherapy remains to be carried out.This article reviews the research progress of adoptive immunotherapy on melanoma.

关 键 词：黑色素瘤 过继性免疫疗法 肿瘤浸润淋巴细胞 

分 类 号：R739.5[医药卫生—肿瘤]